SG11201809856SA - Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors - Google Patents
Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitorsInfo
- Publication number
- SG11201809856SA SG11201809856SA SG11201809856SA SG11201809856SA SG11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA SG 11201809856S A SG11201809856S A SG 11201809856SA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- telangana
- hyderabad
- serene
- avenue
- Prior art date
Links
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940125904 compound 1 Drugs 0.000 abstract 2
- 229940125782 compound 2 Drugs 0.000 abstract 2
- 229940126214 compound 3 Drugs 0.000 abstract 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 2
- 101100075747 Drosophila melanogaster Lztr1 gene Proteins 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 229960003530 donepezil Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -,' Organization 111111111111111111111111111111111111111111111111111111111111111011111111111110111111 International Bureau (10) International Publication Number (43) International Publication Date ...;;• WO 2017/199071 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: Venkateswarlu; Serene Chambers, Road-5, Avenue — 7, A61K 31/31 (2006.01) A61P 25/28 (2006.01) Banjara Hills, Hyderabad,Telangana 500034 (IN). A61K 31/496 (2006.01) (74) Agent: KAPOOR, Divya et al.; Central Square, Suite-328, (21) International Application Number: Plaza III, 20 Manoharlal Khurana Marg, Bara Hindu Rao, PCT/IB2016/054673 (off Rani Jhansi Road), Delhi 110006 (IN). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 03 August 2016 (03.08.2016) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, (26) Publication Language: English EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, (30) Priority Data: LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, 201641017205 18 May 2016 (18.05.2016) IN MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, (71) Applicant: SUVEN LIFE SCIENCES LIMITED PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, [IN/IN]; Serene Chambers, Road-5, Avenue — 7, Banjara SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, Hills, Hyderabad,Telangana 500034 (IN). UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: NIROGI, Ramakrishna; Serene Chambers, (84) Designated States (unless otherwise indicated, for every Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana kind of regional protection available): ARIPO (BW, GH, _ 500034 (IN). SHINDE, Anil Karbhari; Serene Chambers, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = 500034 (IN). JAYARAJAN, Pradeep; Serene Chambers, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Road-5, Avenue — 7, Banjara Hills, Hyderabad,Telangana EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = 500034 (IN). BHYRAPUNENI, Gopinadh; Serene MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, — Chambers, Road-5, Avenue — 7, Banjara Hills, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = Hyderabad,Telangana 500034 (IN). KAMBHAMPATI, KM, ML, MR, NE, SN, TD, TG). Ramasastri; Serene Chambers, Road-5, Avenue — 7, Ban- _ jara Hills, Hyderabad,Telangana 500034 (IN). JASTI, = = (54) Title: COMBINATION = = = 25- = — c.7) 20- = ' ` = ..7.! 15- =— 0 y 1 = OF PURE Open column - Familiar Filled column ' - T 5-HT6 Nowl RECEPTOR ANTAGONISTS object object Figure la WITH ACETYLCHOLINESTERASE INHIBITORS -r- ••••••• _ — = - w — Vehicle Vehicle Compound 1 Compound 1 Compound 2 Compound 2 Compound 3 Compound 3 2 mr/kg, p.n. 2 mt./kg. p.n. 03 mg/kg. p.o. 0.3 mg/kg, p.o. 0.5 mg/kg, p.n. 0.5 mg/kg. p.o. 0.5 mg/kg, p.n. 0.5 mg/kg, p.o. 11 + 1- + + + Vehicle, Donepezil, Vehicle, Doncpzil, Vehicle, Doncpzil, Vehicle, Doncpzil, 1 mi/kg, i.p. 0.05 mg/kg. i.p. 1 14/ kg, i.p. 0.05 mg/kg, i.p. 1 mllkg. i.p. 0.05 mg/kg, i.p 1 mlikg, i.p. 0.05 mg/kg, ip. 11 Data represents Mean ± SEM of Exploration Time 0 01 **p<0.01Vs familiar object (Paired `t test). N=6-33 . 01 Il N .----- (57) : The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in Il combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention © further provides the pharmaceutical composition containing the said combination. ei C [Continued on next page] WO 2017/199071 Al MIDEDIMOMOIDEIROIDEMOMOHEIMONMOIllii0#011# Declarations under Rule 4.17: — as to applicant's entitlement to apply patent (Rule 4.17(H)) for and be granted a Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017205 | 2016-05-18 | ||
| PCT/IB2016/054673 WO2017199071A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809856SA true SG11201809856SA (en) | 2018-12-28 |
Family
ID=56940098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809856SA SG11201809856SA (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11458135B2 (en) |
| EP (1) | EP3484467B1 (en) |
| JP (1) | JP6606299B2 (en) |
| KR (1) | KR102015484B1 (en) |
| CN (2) | CN114642667A (en) |
| AU (1) | AU2016407427B2 (en) |
| BR (1) | BR112018073419A2 (en) |
| CA (1) | CA3023819C (en) |
| CY (1) | CY1123013T1 (en) |
| DK (1) | DK3484467T3 (en) |
| EA (1) | EA036347B1 (en) |
| ES (1) | ES2796181T3 (en) |
| HR (1) | HRP20200872T1 (en) |
| HU (1) | HUE050819T2 (en) |
| IL (1) | IL262921B (en) |
| LT (1) | LT3484467T (en) |
| MA (1) | MA45639B1 (en) |
| MD (1) | MD3484467T2 (en) |
| ME (1) | ME03731B (en) |
| MX (1) | MX2018014185A (en) |
| NZ (1) | NZ748280A (en) |
| PL (1) | PL3484467T3 (en) |
| PT (1) | PT3484467T (en) |
| RS (1) | RS60422B1 (en) |
| SG (1) | SG11201809856SA (en) |
| SI (1) | SI3484467T1 (en) |
| WO (1) | WO2017199071A1 (en) |
| ZA (1) | ZA201807468B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084768A (en) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | Use of gemfibrozil and derivatives thereof for treating and/or preventing neurodegenerative diseases |
| CN111084776A (en) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | Use of pilenicacid and derivatives thereof for treating and/or preventing neurodegenerative diseases |
| JP7556031B2 (en) * | 2019-12-02 | 2024-09-25 | スヴェン・ライフ・サイエンシーズ・リミテッド | Treating behavioral and psychological symptoms in people with dementia |
| BR112022010540A2 (en) | 2019-12-02 | 2022-08-16 | Suven Life Sciences Ltd | METHODS TO TREAT BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN PATIENTS WITH DEMENTIA |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1581492T3 (en) * | 2002-11-28 | 2008-11-10 | Suven Life Sciences Ltd | N-arylsulfonyl-3-substituted indoles with serotonin receptor affinity, process for their preparation and a pharmaceutical composition containing these |
| PE20071143A1 (en) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | PHARMACEUTICAL COMPOSITION INCLUDING AN ACETYLCHOLINESTERASE INHIBITOR AND A 5-HYDROXITRIPTAMINE-6 ANTAGONIST |
| MX2008015996A (en) * | 2006-06-23 | 2009-01-20 | Esteve Labor Dr | Combination of a cholinesterase inhibitor and a compound with 5-ht6 receptor affinity. |
| AR061637A1 (en) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | SNC DISORDER TREATMENT COMPOSITIONS AND METHODS |
| JO3459B1 (en) | 2012-09-09 | 2020-07-05 | H Lundbeck As | Pharmaceutical compositions for treating alzheimer's disease |
| ME02843B (en) | 2013-12-02 | 2018-01-20 | Suven Life Sciences Ltd | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1h-indole dimesylate monohydrate |
-
2016
- 2016-08-03 EA EA201892529A patent/EA036347B1/en unknown
- 2016-08-03 AU AU2016407427A patent/AU2016407427B2/en active Active
- 2016-08-03 JP JP2018559336A patent/JP6606299B2/en active Active
- 2016-08-03 DK DK16766622.1T patent/DK3484467T3/en active
- 2016-08-03 PL PL16766622T patent/PL3484467T3/en unknown
- 2016-08-03 RS RS20200635A patent/RS60422B1/en unknown
- 2016-08-03 CA CA3023819A patent/CA3023819C/en active Active
- 2016-08-03 CN CN202210321209.2A patent/CN114642667A/en active Pending
- 2016-08-03 ES ES16766622T patent/ES2796181T3/en active Active
- 2016-08-03 ME MEP-2020-109A patent/ME03731B/en unknown
- 2016-08-03 MX MX2018014185A patent/MX2018014185A/en unknown
- 2016-08-03 NZ NZ748280A patent/NZ748280A/en unknown
- 2016-08-03 MA MA45639A patent/MA45639B1/en unknown
- 2016-08-03 PT PT167666221T patent/PT3484467T/en unknown
- 2016-08-03 CN CN201680085574.0A patent/CN109069468A/en active Pending
- 2016-08-03 SI SI201630791T patent/SI3484467T1/en unknown
- 2016-08-03 KR KR1020187035983A patent/KR102015484B1/en active IP Right Grant
- 2016-08-03 EP EP16766622.1A patent/EP3484467B1/en active Active
- 2016-08-03 US US16/099,161 patent/US11458135B2/en active Active
- 2016-08-03 BR BR112018073419-5A patent/BR112018073419A2/en not_active Application Discontinuation
- 2016-08-03 HU HUE16766622A patent/HUE050819T2/en unknown
- 2016-08-03 MD MDE20190594T patent/MD3484467T2/en unknown
- 2016-08-03 SG SG11201809856SA patent/SG11201809856SA/en unknown
- 2016-08-03 LT LTEP16766622.1T patent/LT3484467T/en unknown
- 2016-08-03 WO PCT/IB2016/054673 patent/WO2017199071A1/en unknown
-
2018
- 2018-11-07 ZA ZA2018/07468A patent/ZA201807468B/en unknown
- 2018-11-11 IL IL262921A patent/IL262921B/en active IP Right Grant
-
2020
- 2020-05-29 CY CY20201100489T patent/CY1123013T1/en unknown
- 2020-06-02 HR HRP20200872TT patent/HRP20200872T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
| SG11201901995TA (en) | Crystalline and salt forms of ppar agonist compounds | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201810389XA (en) | New antibacterial compounds | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201407402TA (en) | Carbazole-containing sulfonamides as cryptochrome modulators | |
| SG11201809856SA (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |